I didn't say that it will be a 2A. I simply quoted what
I didn't say that it will be a 2A. I simply quoted what was reported from the shareholder meeting which I consider the bar at which point BP "will be knocking our door down". Whether it is a "full blown" Phase 2 or not, it was stated today as a 6 week study so I do not think it will be an expensive study. We will have to wait for more details to guesstimate the associated cost but I believe your guess is way too high. Whatever the cost is I believe the funds are identified and we will probably hear more details between now and when the trial commences.
6
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Hyzon Motors Announces Delisting from Nasdaq Hyzon Motors Inc. is making a significant shift regarding its stock trading status. This U.S. company, known for its commitment to high-performance hydrogen fuel cell technology, has decided to inform Nasdaq Stock Market of its intent to delist its Class A common stock and publicly traded warrants. This move comes as part of...
Continue Reading
Your Gateway to High Returns in Crypto Staking As the digital currency landscape continues to expand, platforms like Keynode.net are leading the charge in offering unprecedented opportunities for investors. For those seeking impressive annual percentage yields (APY) through crypto staking, Keynode.net has emerged as a premier choice. Its user-friendly interface, robust...
Continue Reading
Overview of the Class Action Lawsuit Against Rocket Pharmaceuticals Pomerantz LLP has initiated a class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) highlighting various concerns regarding the company's business practices. Investors who have suffered losses during the stipulated Class Period should take note of this unfolding situation. Key Details...
Continue Reading
Revitalizing Economic Growth at the 23rd SMDO Conference The 23rd Annual South Metro Development Outlook (SMDO25) Conference stands as a pivotal forum for industry leaders, policymakers, and community stakeholders. It is designed to foster collaboration and tackle some of the most pressing issues faced by the region today. Set against the backdrop of changing federal...
Continue Reading
Strong First Quarter Results for SciBase In the recent interim report, SciBase has showcased an impressive performance for the first quarter of 2025. The medical technology company, renowned for its innovative dermatological solutions, recorded net sales of TSEK 8,856, marking a remarkable increase of 46% from the previous year’s figures. Financial Performance Overview...
Continue Reading
